DUOdopa/Duopa in Patients With Advanced Parkinson's Disease (PD) - a GLobal Observational Study Evaluating Long-Term Effectiveness (DUOGLOBE)

Trial Profile

DUOdopa/Duopa in Patients With Advanced Parkinson's Disease (PD) - a GLobal Observational Study Evaluating Long-Term Effectiveness (DUOGLOBE)

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 02 May 2018

At a glance

  • Drugs Levodopa/carbidopa (Primary)
  • Indications Parkinson's disease
  • Focus Therapeutic Use
  • Acronyms DUOGLOBE
  • Sponsors AbbVie
  • Most Recent Events

    • 27 Apr 2018 Results (n=29) assessing long-term effectiveness of levodopa-carbidopa intestinal gel (LCIG) treatment in advanced Parkinson disease (PD) patients under routine clinical care, were presented at the 70th Annual Meeting of the American Academy of Neurology.
    • 02 Feb 2018 Status changed from recruiting to active, no longer recruiting.
    • 12 May 2017 Planned End Date changed from 1 Dec 2020 to 27 Mar 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top